| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802525301116 | 252530111 | XOZAL F.C.TAB 5MG/TAB BTx30 (ΣΕ BLISTER) | 3.33 | 3.49 | 4.81 |
| 05/2018 | 2802525302038 | 252530203 | XOZAL OR.SO.D 5MG/1ML FL x 20 ML | 04.06 | 4.26 | 5.87 |
| 05/2018 | 2802525303011 | 252530301 | XOZAL ORAL.SOL 0,5MG/ML BOTTLE x 200 ML | 3.91 | 4.10 | 5.65 |
For the relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria
Cetirizine competes with histamine for binding at H<sub>1</sub>-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The low incidence of sedation can be attributed to reduced penetration of cetirizine into the CNS as a result of the less lipophilic carboxyl group on the ethylamine side chain.
Somnolence (sleepiness or unusual drowsiness), restlessness, irritability
mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours postdose was observed for cetirizine
8.3 hours
* 53 mL/min [healthy]